Antibacterial drugs: Redesigned antibiotic combats drug-resistant tuberculosis

Nature Reviews Drug Discovery

Volumn 13, Issue 4, 2014, Pages 256-257

  Cully, Megan ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMPICIN; SPECTINAMIDE DERIVATIVE; SPECTINOMYCIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; BACTERIAL LOAD; CRYSTAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG RESISTANT TUBERCULOSIS; DRUG SAFETY; DRUG STRUCTURE; GONORRHEA; HUMAN; MITOCHONDRIAL TOXICITY; MOLECULAR DYNAMICS; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NOTE; PRIORITY JOURNAL; TUBERCULOSIS;

AMIDES; ANIMALS; ANTITUBERCULAR AGENTS; DRUG DESIGN; MODELS, MOLECULAR; MYCOBACTERIUM TUBERCULOSIS; SPECTINOMYCIN; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84898600294     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4287     Document Type: Note

References (2)

1. Lee, R. E. et al. Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux. Nature Med. 20, 152-158 (2014)
2. Zumla, A., Nahid, P. & Cole, S. T. Advances in the development of new tuberculosis drugs and treatment regimens. Nature Rev. Drug Discov. 12, 388-404 (2013)